| 29408302 |
The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders
Roskoski, R
|
Pharmacol. Res. |
2018 |
| 12660384 |
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
Marynen, P,
Boogaerts, M,
Griffin, JD,
Galinsky, I,
Cortes, J,
Coutré, SE,
Kantarjian, H,
Schmid, J,
Malone, J,
Schrier, SL,
Cools, J,
Stover, EH,
Wlodarska, I,
Kutok, J,
Rose, M,
Verhoef, G,
Vandenberghe, P,
Gotlib, J,
Gilliland, DG,
Alam, R,
Clark, J,
Legare, RD,
Cross, NC,
Stone, R,
Deangelo, DJ,
Tefferi, A
|
N. Engl. J. Med. |
2003 |
| 12522257 |
PDGFRA activating mutations in gastrointestinal stromal tumors
Corless, CL,
Heinrich, MC,
Singer, S,
Griffith, DJ,
Town, A,
Haley, A,
Duensing, A,
McGreevey, L,
Fletcher, JA,
Demetri, GD,
Joseph, N,
Chen, CJ,
Fletcher, CD
|
Science |
2003 |
| 18234315 |
Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia
Yousefi, S,
Simon, D,
Salemi, S,
Simon, HU
|
J. Allergy Clin. Immunol. |
2008 |
| 19210352 |
A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome
Scapozza, L,
Simon, D,
Salemi, S,
Moretti, L,
Simon, HU,
Yousefi, S,
Schmid, I
|
Allergy |
2009 |
| 22665524 |
Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors
Fletcher, JA,
Mariño-Enríquez, A,
Heinrich, MC,
Donsky, RS,
Presnell, A,
Griffith, DJ,
McKinley, A,
Liang, CW,
Patterson, J,
Taguchi, T
|
Mol. Cancer Ther. |
2012 |
| 16645167 |
Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant
Marynen, P,
Boogaerts, M,
Folens, C,
Vandenberghe, P,
Mentens, N,
Scheers, W,
Lierman, E,
Cools, J,
Van Miegroet, H,
Stover, EH
|
Blood |
2006 |
| 29964125 |
Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases
Heinrich, MC,
Kent, JD,
Klug, LR
|
Pharmacol. Ther. |
2018 |
| 29093181 |
A precision therapy against cancers driven by KIT/PDGFRA mutations
Heinrich, MC,
Zhang, Y,
Hodous, BL,
Shutes, A,
Lengauer, C,
Evans, EK,
Kohl, N,
Wolf, B,
Schöffski, P,
Zhu, XJ,
Kim, JL,
Gebreyohannes, YK,
Gardino, AK,
Wozniak, A,
DiPietro, L,
Lydon, N,
Wilson, K,
Brooijmans, N,
Schmidt-Kittler, O,
Boral, A,
Miller, S,
LaBranche, TP,
Deangelo, DJ,
Davis, A,
Guzi, T,
Wilson, D
|
Sci Transl Med |
2017 |
| 15928335 |
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib
Shiraga, S,
McGreevey, L,
Schroeder, A,
Corless, CL,
Heinrich, MC,
Harrell, P,
Morich, J,
Bainbridge, T,
Town, A,
Griffith, D
|
J. Clin. Oncol. |
2005 |
| 31085175 |
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Hood, MM,
Gupta, A,
Su, Y,
Ensinger, CL,
Caldwell, TM,
Bulfer, SL,
Heinrich, MC,
Al-Ani, G,
Ahn, YM,
Patt, WC,
Janku, F,
Turner, BA,
Ruiz-Soto, R,
Leary, CB,
Abdul Razak, AR,
Yates, K,
Town, A,
Rosen, O,
Wise, SC,
Vogeti, L,
Telikepalli, H,
Rutkoski, TJ,
Vogeti, S,
Smith, BD,
Flynn, DL,
Chun, L,
Lu, WP,
Kaufman, MD,
McKinley, A
|
Cancer Cell |
2019 |
